Early Phase Development

An Intelligent Drug Development Paradigm

August 03, 2023

An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.

Exploring an Intelligent Drug Development Paradigm

August 02, 2023

An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.

Chime Biologics Forms mAb Development and Manufacturing Deal with Leads Biolabs and BeiGene

July 06, 2023

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

Using Smart Tools for Smart Development

May 03, 2023

The use of smart tools in early drug discovery can have an impact on downstream phases of drug development.

High-titre Vector Producing Cells

April 02, 2023

Decreasing vein to vein time saves lives.

Advances in In Vivo CAR T-cell Therapies

March 01, 2023

Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.

Technology for In Vivo CAR T-cell Therapy Advances

February 02, 2023

In vivo CAR-T gene therapies could resolve challenges faced by autologous and allogeneic treatments.

The Power of PK/PD in mAb Development

December 03, 2022

Although well known in R&D, PK/PD studies are an equally powerful tool for promoting successful biologic drug development.

ADME Studies: Determining Promising Drug Compounds

November 02, 2022

Experts discuss factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.

Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk

October 16, 2022

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.